Version 1
: Received: 14 September 2023 / Approved: 22 September 2023 / Online: 22 September 2023 (04:36:12 CEST)
How to cite:
Alkattan, A.; Alsalameen, E.; Harmoush, A.; Farawati, M.N.; Alsharif, H.; Mahmoud, N.; Farawati, M.A.; Alfaleh, A.; Kandeel, M.; Radwan, N. A Review and Meta-Analysis of the Effect of Atenolol on All-Cause Mortality Risk among Asians With Chronic Progressive Diseases. Preprints2023, 2023091522. https://doi.org/10.20944/preprints202309.1522.v1
Alkattan, A.; Alsalameen, E.; Harmoush, A.; Farawati, M.N.; Alsharif, H.; Mahmoud, N.; Farawati, M.A.; Alfaleh, A.; Kandeel, M.; Radwan, N. A Review and Meta-Analysis of the Effect of Atenolol on All-Cause Mortality Risk among Asians With Chronic Progressive Diseases. Preprints 2023, 2023091522. https://doi.org/10.20944/preprints202309.1522.v1
Alkattan, A.; Alsalameen, E.; Harmoush, A.; Farawati, M.N.; Alsharif, H.; Mahmoud, N.; Farawati, M.A.; Alfaleh, A.; Kandeel, M.; Radwan, N. A Review and Meta-Analysis of the Effect of Atenolol on All-Cause Mortality Risk among Asians With Chronic Progressive Diseases. Preprints2023, 2023091522. https://doi.org/10.20944/preprints202309.1522.v1
APA Style
Alkattan, A., Alsalameen, E., Harmoush, A., Farawati, M.N., Alsharif, H., Mahmoud, N., Farawati, M.A., Alfaleh, A., Kandeel, M., & Radwan, N. (2023). A Review and Meta-Analysis of the Effect of Atenolol on All-Cause Mortality Risk among Asians With Chronic Progressive Diseases. Preprints. https://doi.org/10.20944/preprints202309.1522.v1
Chicago/Turabian Style
Alkattan, A., Mahmoud Kandeel and Nashwa Radwan. 2023 "A Review and Meta-Analysis of the Effect of Atenolol on All-Cause Mortality Risk among Asians With Chronic Progressive Diseases" Preprints. https://doi.org/10.20944/preprints202309.1522.v1
Abstract
Background: The current review was conducted to determine the effectiveness of atenolol on all-cause mortality rate among Asian patients with chronic progressive diseases, mainly diabetes mellitus, primary hypertension, and coronary artery disease.
Methods: We searched the COCHRANE, MEDLINE, TRIP, and EMBASE databases for published articles up to 31 March 2023. Studies that compared all-cause mortality rates among Asian patients who were on atenolol or other medications were included.
Results: The review included 79603 Asian patients from three cohort studies. Out of the studied patients, 36046 were atenolol users and 43557 were non-atenolol users. The review revealed that atenolol users recorded lower all-cause mortality rates compared to non-users with a significant difference (OR= 0.57, CI= 0.44-0.75, P<0.001). The pooled estimate of the all-cause mortality rate was also lower among atenolol users (7.02%) compared to metoprolol tartrate users (13.15%) with a significant difference (OR= 0.50, CI= 0.47-0.53, p < 0.0001). Although the included studies were categorized as having a low risk of bias for most of the studied domains, significant heterogeneity was recorded across these studies (I2 =88%, P=0.001).
Conclusion: This review found that atenolol when compared to a control or metoprolol tartrate, has a significant effect in reducing the all-cause mortality rate among Asian patients with chronic progressive disease.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
